Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13
Vaxart (NASDAQ: VXRT) has scheduled its third quarter 2024 business update and financial results conference call for November 13, 2024, after market close. The senior management team will host the call at 4:30 p.m. ET. Investors can participate via webcast or telephone, with domestic and international dial-in numbers provided. Written questions can be submitted in advance to ir@vaxart.com. A replay will be available on the company's website after the event.
Vaxart (NASDAQ: VXRT) ha programmato la sua aggiornamento aziendale e i risultati finanziari per il terzo trimestre del 2024 per il 13 novembre 2024, dopo la chiusura del mercato. Il team di alta direzione ospiterà la chiamata alle 16:30 ET. Gli investitori possono partecipare tramite webcast o telefono, con numeri di accesso nazionali e internazionali forniti. È possibile inviare domande scritte in anticipo a ir@vaxart.com. Una registrazione sarà disponibile sul sito web dell'azienda dopo l'evento.
Vaxart (NASDAQ: VXRT) ha programado su actualización de negocios y conferencia sobre los resultados financieros del tercer trimestre de 2024 para el 13 de noviembre de 2024, después del cierre del mercado. El equipo de alta dirección realizará la llamada a las 4:30 p.m. ET. Los inversores pueden participar a través de webcast o teléfono, con números para marcar nacionales e internacionales proporcionados. Se pueden enviar preguntas por escrito con antelación a ir@vaxart.com. Una repetición estará disponible en el sitio web de la empresa después del evento.
Vaxart (NASDAQ: VXRT)는 2024년 3분기 사업 업데이트 및 재무 결과 회의를 2024년 11월 13일, 시장 마감 후에 실시할 예정입니다. 고위 경영진이 동부 표준시(ET) 오후 4시 30분에 전화를 주관합니다. 투자자들은 웹캐스트 또는 전화로 참여할 수 있으며, 국내 및 국제 전화 접속 번호가 제공됩니다. 서면 질문은 미리 ir@vaxart.com으로 제출할 수 있습니다. 행사 이후 회사 웹사이트에서 녹음본을 확인할 수 있습니다.
Vaxart (NASDAQ: VXRT) a programmé sa mise à jour commerciale et sa conférence sur les résultats financiers pour le troisième trimestre 2024 pour le 13 novembre 2024, après la fermeture du marché. L'équipe de direction animera l'appel à 16h30 ET. Les investisseurs peuvent participer par webdiffusion ou par téléphone, avec des numéros d'appel nationaux et internationaux fournis. Des questions écrites peuvent être soumises à l'avance à ir@vaxart.com. Un enregistrement sera disponible sur le site web de l'entreprise après l'événement.
Vaxart (NASDAQ: VXRT) hat sein Update zum Geschäft und die Finanzberichte für das dritte Quartal 2024 für den 13. November 2024, nach Börsenschluss, angesetzt. Das Managementteam wird das Gespräch um 16:30 Uhr ET leiten. Investoren können über Webcast oder Telefon teilnehmen, wobei nationale und internationale Telefonnummern bereitgestellt werden. Schriftliche Fragen können im Voraus an ir@vaxart.com gesendet werden. Eine Wiederholung wird nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.
The conference call can be accessed using the following information:
Webcast: Click here
Date: Wednesday, November 13, 2024 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13749666
Investors may submit written questions in advance of the conference call to ir@vaxart.com.
A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
FAQ
When will Vaxart (VXRT) report Q3 2024 earnings?
What time is Vaxart's (VXRT) Q3 2024 earnings call?
How can investors participate in Vaxart's (VXRT) Q3 2024 earnings call?